2018
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, Diéras V, Hegg R, Im SA, Shaw Wright G, Henschel V, Molinero L, Chui SY, Funke R, Husain A, Winer EP, Loi S, Emens LA. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. New England Journal Of Medicine 2018, 379: 2108-2121. PMID: 30345906, DOI: 10.1056/nejmoa1809615.Peer-Reviewed Original ResearchConceptsMetastatic triple-negative breast cancerTriple-negative breast cancerProgression-free survivalMedian progression-free survivalMedian overall survivalNab-paclitaxelBreast cancerOverall survivalPD-L1Adverse eventsTreat analysisPositive tumorsAdvanced triple-negative breast cancerDeath ligand 1 (PD-L1) expressionAdjuvant taxane therapyPrimary end pointLigand 1 expressionPhase 3 trialNew adverse effectsTreat populationTaxane therapyLiver metastasesAggressive diseasePoor outcomeSafety profile
2017
Genome-wide copy number analysis of cell-free DNA from patients with chemotherapy-resistant metastatic triple-negative breast cancer.
Stover D, Parsons H, Ha G, Freeman S, Barry W, Guo H, Gydush G, Reed S, Rhoades J, Rotem D, Hughes M, Krop I, Tolaney S, Wagle N, Getz G, Meyerson M, Love J, Winer E, Lin N, Adalsteinsson V. Genome-wide copy number analysis of cell-free DNA from patients with chemotherapy-resistant metastatic triple-negative breast cancer. Journal Of Clinical Oncology 2017, 35: 1092-1092. DOI: 10.1200/jco.2017.35.15_suppl.1092.Peer-Reviewed Original ResearchTriple-negative breast cancerMetastatic triple-negative breast cancerCell-free DNAMetastatic TNBCFirst blood drawCopy number alterationsOverall survivalBlood drawBreast cancerPrimary triple-negative breast cancerTumor fractionMedian overall survivalBreast cancer subsetsIndependent prognostic markerPlasma samplesNovel therapeutic targetCopy number analysisNumber alterationsHazard ratioLiver metastasesGenome-wide copy number analysisMetastatic diagnosisBRCA statusPrognostic markerCancer subsets
2008
Breast surgery in stage IV breast cancer: impact of staging and patient selection on overall survival
Bafford AC, Burstein HJ, Barkley CR, Smith BL, Lipsitz S, Iglehart JD, Winer EP, Golshan M. Breast surgery in stage IV breast cancer: impact of staging and patient selection on overall survival. Breast Cancer Research And Treatment 2008, 115: 7-12. PMID: 18581232, DOI: 10.1007/s10549-008-0101-7.Peer-Reviewed Original ResearchConceptsStage IV breast cancerOverall survivalBreast cancerStage IV breast carcinomaMedian overall survivalDatabase of patientsAdverse predictorsHer2neu statusUnderwent mastectomySurgery groupLiver metastasesMedian survivalMetastatic diseaseBreast surgeryTherapeutic surgeryBreast carcinomaNS groupRetrospective analysisStaging factorsSurgerySurvivalWomenPatientsMultivariate survivalCancer